Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Ophthalmol. 2024 Sep 1;72(9):1267-1274. doi: 10.4103/IJO.IJO_416_24. Epub 2024 Aug 23.
To assess the visual and clinical outcomes after bilateral implantation of the novel extended depth of focus (EDOF) (AcrySof IQ Vivity) intraocular lens (IOL) using a micromonovision strategy.
This was a prospective interventional study at a tertiary care center. Twenty patients (40 eyes) underwent bilateral implantation of AcrySof IQ Vivity IOL. Twelve weeks postoperatively, both uncorrected vision and corrected vision were assessed. Uniocular and binocular defocus curves with and without correction were noted subjectively as well as objectively on I-trace. Contrast sensitivity was assessed with a FACT (Functional Acuity Contrast Testing) machine, and objective parameters like modulation transfer function and Strehl ratio were also measured on I-Trace. Subjective quality of vision using a subjective questionnaire was also evaluated.
The mean binocular postoperative uncorrected distance visual acuity in LogMAR was -0.03 ± 0.09, the uncorrected intermediate visual acuity was 0.03 ± 0.09, and the uncorrected near visual acuity was 0.28 ± 0.18. All defocus curves were smooth and broad with the uncorrected defocus curve (with the micromonovision strategy) better than the corrected defocus curve. The subjective depth of focus (DOF = 3.73) was more than objective DOF (1.93) (P < 0.05). Photopic contrast was better than mesopic at all frequencies. All aberrations increased at 5 mm pupil size compared to 3 mm pupil size and were statistically significant, except for the total eye spherical aberration, which shows no significant difference at 3 mm and 5 mm pupil size (P = 0.27). Spectacle independence for distance, intermediate, and near was achieved in 100%, 94.7%, and 94.7% cases in this study, respectively.
Using the micromonovision strategy, the visual performance of this novel EDOF IOL was outstanding both subjectively and objectively.
评估使用微单视策略行双侧新型扩展景深（EDOF）（AcriSof IQ Vivity）人工晶状体（IOL）植入术后的视力和临床结果。
这是在一家三级护理中心进行的前瞻性干预研究。20 名患者（40 只眼）行双侧 AcriSof IQ Vivity IOL 植入。术后 12 周，评估未矫正视力和矫正视力。主观和客观地在 I-trace 上记录单眼和双眼离焦曲线，包括有和无矫正的情况。使用 FACT（功能性视力对比度测试）机器评估对比敏感度，并且还在 I-Trace 上测量客观参数，如调制传递函数和斯特列尔比。使用主观问卷评估主观视觉质量。
双眼术后未矫正远视力的平均 LogMAR 为-0.03±0.09，未矫正中间视力为 0.03±0.09，未矫正近视力为 0.28±0.18。所有离焦曲线都很平滑且宽阔，未矫正离焦曲线（采用微单视策略）优于矫正离焦曲线。主观景深（景深=3.73）大于客观景深（1.93）（P<0.05）。在所有频率下，明视对比度均优于中间视对比度。与 3mm 瞳孔大小相比，5mm 瞳孔大小时所有像差均增加，且具有统计学意义，除总眼球差外，其在 3mm 和 5mm 瞳孔大小时无显著差异（P=0.27）。在本研究中，100%、94.7%和 94.7%的患者分别实现了对远、中、近距的不依赖眼镜。
使用微单视策略，这种新型 EDOF IOL 的主观和客观视觉性能都非常出色。
